This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with prurigo nodularis.
Sonja Ständer
Advertisement
Sonja Ständer, MD, is a professor of dermatology and neurodermatology for the University of Münster and the head of the interdisciplinary Center for Chronic Pruritus (KCP) at the University Hospital Münster.
Articles by Sonja Ständer
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5